Clinical trials: Topotecan
Ovarian Cancer, Relapses
Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma
The early relapse of ovarian cancer occurring within 6 months of chemotherapy including platinum regimen are called relapses 'platinum resistant' consecutively patients die quickly of their disease.
- Trial name
- ITOV04 (NCT01177501)
- Testing
- Topotecan
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Retinoblastoma
Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma
The investigators are testing subtenon carboplatin in combination with vincristine and topotecan given by vein in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back (recurrent)…
- Trial name
- RELRB1 (NCT00980551)
- Testing
- subtenon Carboplatin, Topotecan Hydrochloride, Vincristine
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Advanced Solid Malignancies
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
- Trial name
- NCT00295243
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Endometrial Cancer
Oral Topotecan With Toripalimab for Patients With Endometrial Cancer
This study aims to explore the safety and efficacy of oral topotecan combined with toripalimab in treating advanced/recurrent endometrial cancer through a single-center, prospective, single-arm, phase II clinical trial.
- Trial name
- NCT06548763
- Testing
- Topotecan, Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Brain Tumors
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors
The investigators plan to improve event free survival rate and reduce treatment related toxicities of pediatric patients with high risk/recurrent CNS tumors by administrating tandem high dose chemotherapy and autologous stem cell…
- Trial name
- NCT01342237
- Testing
- HDCT 1(TTC), HDCT2(MEC)
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Seoul National University Hospital
Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
This phase II trial study has a 6-patient feasibility portion studying the tolerability of chemotherapy with vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients…
- Conditions
- Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT00516295
- Testing
- topotecan hydrochloride, vincristine sulfate, cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003415
- Testing
- amifostine trihydrate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Arizona
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00028743
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 28 sites in Canada
- Volunteers
- 819 people
- Sponsor
- NCIC Clinical Trials Group
Epithelial Ovarian Cancer
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
The purpose of this study is to determine the efficacy and safety of belotecan or topotecan in patients with recurrent or refractory ovarian cancer (AOC).
- Trial name
- NCT01630018
- Testing
- Topotecan, Belotecan
- Where
- South Korea
- Volunteers
- 141 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003297
- Testing
- mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Georgetown University
Myeloma
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
- Trial name
- NCT01039025
- Testing
- Topotecan, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma, WHO Grade III or IV Recurrent Glioma
Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma
Topotecan is a FDA-approved drug when given by intravenous injection, but it is not effective against brain tumors when given intravenously.
- Trial name
- NCT02278510
- Testing
- Topotecan, Gadolinium DTPA, Cleveland Multiport Catheter
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Michael Vogelbaum, MD, PhD
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00064077
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Paclitaxel
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Endometrial Cancer
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00842452
- Testing
- topotecan hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Steven Waggoner, MD
Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Chemotherapy still constitutes the backbone of small-cell lung cancer (SCLC) therapy, particularly in the extensive disease (ED) stage (ED-SCLC).
- Conditions
- Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage, Small Cell Lung Cancer Extensive Stage
- Trial name
- NCT03059667
- Testing
- Atezolizumab, Topotecan, Carboplatin
- Where
- 18 sites in France
- Volunteers
- 73 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Ovarian Cancer
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003732
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Leukemia, Myelodysplastic Syndromes
Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005593
- Testing
- carboplatin, fludarabine phosphate, topotecan hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Case Comprehensive Cancer Center
Ganglioneuroblastoma, Stage 1 Neuroblastoma
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread.
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma
- Trial name
- NCT01798004
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Small Cell Lung Cancer
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
The purpose of this study is to determine whether topotecan plus apatinib are superior to topotecan alone as second-line therapy in small-cell lung cancer.
- Trial name
- NCT02980809
- Testing
- Apatinib, Topotecan
- Volunteers
- 60 people
- Sponsor
- First Hospitals affiliated to the China PLA General Hospital
Ovarian Cancer
SGI-110 in Combination With Carboplatin in Ovarian Cancer
A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin.
- Trial name
- SGI-110 (NCT01696032)
- Testing
- SGI-110, Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine), Carboplatin
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- Astex Pharmaceuticals, Inc.